CEO Daniel de Boer Buys $354K of ProQR Stock at $1.77
PRQR sits 33% above its 52-week low of $1.33.
Summary
ProQR CEO Daniel de Boer purchased $353,960 worth of shares on the open market, reinforcing insider confidence amid recent clinical progress and an activist challenge.
Key Events · Ownership and Investor Activity · PRQR
-
CEO Open-Market Purchase
CEO Daniel de Boer bought 200,000 shares at $1.77 for a total of $353,960 on July 31, 2026, increasing his direct holdings to 500,000 shares.
-
Insider Accumulation Trend
This purchase extends a 90-day pattern of insider buying totaling $988,425 with no open-market sales, signaling strong internal confidence.
-
Activist Pressure Backdrop
The purchase follows a June 3 activist filing by Van Herk Investments (14.6% holder) threatening legal action and a July 29 court petition, making the CEO's buy a notable counter-signal.
-
Recent Positive Clinical Data
The company reported positive Phase 1 target engagement data for AX-0810 on June 25, 2026, and subsequently raised $59.2 million in a premium-priced offering with Eli Lilly participation.
Analysis · PRQR · Life Sciences
CEO Daniel de Boer bought 200,000 shares on the open market for $353,960 at $1.77 per share, lifting his direct stake to 500,000 shares. This is a real-money purchase — not an option exercise or grant — and comes just weeks after the company raised $59.2 million in a premium-priced offering and reported positive Phase 1 data for AX-0810. The buy signals management conviction at a time when an activist investor is pressing for board changes, adding weight to the insider accumulation trend seen over the past 90 days.
How filings like this one have moved
In the 30 days to Sep 15, 2026, 29.9% of the 1678 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.25%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PRQR was trading at $1.77 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $236.1M. The 52-week trading range was $1.33 to $3.10. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.